TomTom And 2 Other High Growth Tech Stocks In Europe

Overview: Pexip Holding ASA is a video technology company offering an end-to-end video conferencing platform and digital infrastructure across the Americas, Europe, the Middle East, Africa, and the Asia Pacific with a market cap of NOK6.42 billion.

Operations: The company generates revenue primarily from the sale of collaboration services, amounting to NOK1.19 billion.

Pexip Holding’s recent performance underscores its emerging strength in the tech sector, with a notable 20.7% expected annual earnings growth outpacing the Norwegian market’s 13.3%. This growth is supported by an impressive increase in net income to NOK 43.88 million from NOK 7.03 million year-over-year for Q2 2025, reflecting robust operational efficiency and market adaptation. Furthermore, Pexip’s strategic share repurchases, totaling 1,685,437 shares for NOK 99.9 million, signify a confident reinvestment back into the company’s core capabilities and future potential in software solutions—a sector where innovation directly translates to competitive advantage and customer value.

OB:PEXIP Earnings and Revenue Growth as at Sep 2025

Simply Wall St Growth Rating: ★★★★★☆

Overview: BioGaia AB (publ) is a healthcare company that develops, manufactures, markets, and sells probiotic products for gut, oral, and immune health across various regions including Europe and the United States; it has a market cap of approximately SEK11.07 billion.

Operations: BioGaia generates revenue primarily through its Pediatrics segment, which accounts for SEK1.08 billion, followed by the Adult Health segment at SEK352.62 million. The company’s operations span multiple regions, focusing on probiotic products for various health applications.

BioGaia’s strategic expansion into direct distribution in Germany and Austria, starting early 2026, leverages its strong position in the probiotics market, projected to grow at a 5% CAGR until 2030. Despite a recent dip in net income from SEK 111.01 million to SEK 87.91 million year-over-year for Q2 2025, the company’s earnings are expected to surge by an impressive annual rate of 21.3%. This growth is underpinned by BioGaia’s commitment to R&D, notably its PEARL study outcomes which enhance its reputation in pediatric care through proven probiotic benefits.

OM:BIOG B Revenue and Expenses Breakdown as at Sep 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTAM:TOM2 OB:PEXIP and OM:BIOG B.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com